Long-term durability of immune responses to the BNT162b2 and mRNA-1273 vaccines based on dosage, age and sex
Abstract The lipid nanoparticle (LNP)-formulated mRNA vaccines BNT162b2 and mRNA-1273 are a widely adopted multi vaccination public health strategy to manage the COVID-19 pandemic. Clinical trial data has described the immunogenicity of the vaccine, albeit within a limited study time frame. Here, we...
Main Authors: | Chapin S. Korosec, Suzan Farhang-Sardroodi, David W. Dick, Sameneh Gholami, Mohammad Sajjad Ghaemi, Iain R. Moyles, Morgan Craig, Hsu Kiang Ooi, Jane M. Heffernan |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-12-01
|
Series: | Scientific Reports |
Online Access: | https://doi.org/10.1038/s41598-022-25134-0 |
Similar Items
-
Analysis of Host Immunological Response of Adenovirus-Based COVID-19 Vaccines
by: Suzan Farhang-Sardroodi, et al.
Published: (2021-08-01) -
A machine learning approach to differentiate between COVID-19 and influenza infection using synthetic infection and immune response data
by: Suzan Farhang-Sardroodi, et al.
Published: (2022-04-01) -
Pharmaceutical and non-pharmaceutical interventions for controlling the COVID-19 pandemic
by: Jeta Molla, et al.
Published: (2023-12-01) -
Cellular and Humoral Responses in Dialysis Patients after Vaccination with the BNT162b2 or mRNA-1273 Vaccines
by: Ilias Mavrovouniotis, et al.
Published: (2023-02-01) -
Comparison of antibody response durability of mRNA-1273, BNT162b2, and Ad26.COV2.S SARS-CoV-2 vaccines in healthcare workers
by: Wendy M. Brunner, et al.
Published: (2022-10-01)